Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

NCT04260698 is registered in ClinicalTrials.gov with Gamida Cell ltd as lead sponsor.

NCT NCT04260698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Lead sponsor
Gamida Cell ltd
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2020
Completion date
May 8, 2025
Enrollment
36 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancies